Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Heat Wave Fuels Massive Wildfire In Australia - 2Hubble Space Telescope spies dusty debris from two cosmic collisions
- 3Police arrest 18 as anti-war protests spread across Tel Aviv, Haifa, Jerusalem
- 4Can humans have babies in space? It may be harder than expected
- 5Unwinding the Starting points of America: An Excursion Through History
- Vote In favor of Your Favored Occasion Arranging Administration
- The biggest black hole breakthroughs of 2025
- Excelling at Discussion: Genuine Examples of overcoming adversity
- IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- 1st-ever disease gene fix, Alzheimer's blood test: 7 medical breakthroughs in 2025
- FDA updates risk classification for voluntary shredded cheese recall
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- Investigating Free Cell Phones: What You Really want to Be aware
